The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 26.e1-26.e7

  Mikel Hubanks, J ^a   Boorjian, Stephen A ^a   Frank, Igor ^a   Gettman, Matthew T ^a   Houston Thompson, R ^a   Rangel, Laureano J ^a   Bergstralh, Eric J ^a   Jeffrey Karnes, R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Extracapsular extension; Prostate cancer; Radical prostatectomy; Seminal vesicle

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; RISK FACTOR; SEMINAL VESICLE; TUMOR INVASION; DISEASE COURSE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; REGISTER; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

AGED; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEMINAL VESICLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84890787895     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.09.002     Document Type: Article

References (30)

1. Schellhammer P.F. Radical prostatectomy. Patterns of local failure and survival in 67 patients. Urology 1988, 31:191-197.
2. Freedland S.J., Aronson W.J., Presti J.C., et al. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer 2004, 100:1633-1638.
3. Eggener S.E., Roehl K.A., Smith N.D., et al. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy. J Urol 2005, 173:1150-1155.
4. Sofer M., Savoie M., Kim S.S., Civantos F., Soloway M.S. Biochemical and pathological predictors of the recurrence of prostatic adenocarcinoma with seminal vesicle invasion. J Urol 2003, 169:153-156.
5. Pierorazio P.M., Ross A.E., Schaeffer E.M., et al. A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy. J Urol 2011, 185:1691-1697.
6. Tefilli M.V., Gheiler E.L., Tiguert R., et al. Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. J Urol 1998, 160:802-806.
7. Siddiqui S.A., Boorjian S.A., Blute M.L., et al. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. Br J Urol Int 2011, 107:383-388.
8. Johnson C.W., McKiernan J.M., Anastasiadis A.G., et al. Prognostic indicators for long term outcome following radical retropubic prostatectomy for prostate cancer involving the seminal vesicles. Urol Oncol 2004, 22:107-111.
9. Ohori M., Scardino P.T., Lapin S.L., Seale-Hawkins C., Link J., Wheeler T.M. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol 1993, 17:1252-1261.
10. Carver B.S., Bianco F.J., Scardino P.T., Eastham J.A. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006, 176:564-568.
11. Schild S.E., Wong W.W., Grado G.L., et al. The results of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys 1996, 34:535-541.
12. Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J.I., Walsh P.C. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003, 169:517-523.
13. Hull G.W., Rabbani F., Abbas F., Wheeler T.M., Kattan M.W., Scardino P.T. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002, 167:528-534.
14. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. Br J Urol Int 2004, 95:751-756.
15. Swanson G.P., Goldman B., Tangen C.M., et al. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol 2008, 180:2453-2457.
16. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005, 366:572-578.
17. Thompson I.M., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. J Am Med Assoc 2006, 296:2329-2335.
18. Wiegel T., Bottke D., Steiner U., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27:2924-2930.
19. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009, 181:956-962.
20. Ward J.F., Blute M.L., Slezak J., Bergstralh E.J., Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003;170:1872-6.
21. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. J Am Med Assoc 2005, 294:433-439.
22. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999, 281:1591-1597.
23. Boorjian S.A., Thompson R.H., Tollefson M.K., et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011, 59:893-899.
24. Amling C.L., Bergstralh E.J., Blute M.L., Slezak J.M., Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol 2001, 165:1146-1151.
25. Stephenson A.J., Kattan M.W., Eastham J.A., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006, 24:3973-3978.
26. Boorjian S.A., Karnes R.J., Crispen P.L., Rangel L.J., Bergstralh E.J., Blute M.L. Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol 2009, 182:2708-2714.
27. Boorjian S.A., Karnes R.J., Crispen P.L., et al. The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol 2010, 183:1003-1009.
28. Keating N.L., O'Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24:4448-4456.
29. Dorff T.B., Flaig T.W., Tangen C.M., et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011, 29:2040-2045.
30. Boorjian S.A., Thompson R.H., Siddiqui S., et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007, 178:864-870.